ISSN:
1432-2072
Keywords:
Key words Bromperidol
;
Reduced bromperidol
;
Plasma concentration
;
Metabolism
;
CYP2D6 genotype
;
Flunitrazepam
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract The effects of various factors, including the cytochrome P450 (CYP) 2D6 genotype and the coadministration of flunitrazepam, on the steady-state plasma concentrations (Css) of bromperidol and its reduced metabolite were studied in 62 schizophrenic inpatients receiving bromperidol 12 mg/day. By use of allele-specific PCR analysis, the wild type allele (CYP2D6 * 1A) and four mutated alleles causing either absent (CYP2D6 * 3, CYP2D6 * 4 and CYP2D6 * 5) or decreased (CYP2D6 * 10) CYP2D6 activity were identified. The means (ranges) of the Css of bromperidol and reduced bromperidol corrected to the median body weight were 7.2 (1.3–17.4) and 2.2 (0.4–8.9) ng/ml, respectively. Neither the Css of bromperidol nor that of reduced bromperidol significantly differed among the patients with no (n = 28), one (n = 30) and two mutated alleles (n = 4). The patients coadministered with flunitrazepam (n = 52) had significantly (P 〈 0.05) higher Css of bromperidol, but not reduced bromperidol, than those not (n = 10). Age, sex and smoking had no significant effects on the Css of these compounds. The present study thus suggests that the polymorphic CYP2D6 is not involved in the metabolism of bromperidol and reduced bromperidol to a major extent. The coadministration of flunitrazepam inhibits the metabolism of bromperidol, but age, sex and smoking do not affect it.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/s002130050519
Permalink
